Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
9.02
+2.17 (31.68%)
At close: Mar 9, 2026, 4:00 PM EDT
9.20
+0.18 (2.00%)
After-hours: Mar 9, 2026, 5:41 PM EDT
Cartesian Therapeutics Revenue
In the year 2025, Cartesian Therapeutics had annual revenue of $2.80M, down -92.81%. Cartesian Therapeutics had revenue of $947.00K in the quarter ending December 31, 2025, a decrease of -224.77%.
Revenue (ttm)
$2.80M
Revenue Growth
-92.81%
P/S Ratio
79.12
Revenue / Employee
$42,379
Employees
66
Market Cap
234.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.80M | -36.12M | -92.81% |
| Dec 31, 2024 | 38.91M | 12.91M | 49.64% |
| Dec 31, 2023 | 26.00M | -84.77M | -76.53% |
| Dec 31, 2022 | 110.78M | 25.70M | 30.21% |
| Dec 31, 2021 | 85.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 244.06M |
| Protalix BioTherapeutics | 61.84M |
| Editas Medicine | 40.52M |
| Voyager Therapeutics | 31.32M |
| Sol-Gel Technologies | 18.97M |
| MediWound | 16.96M |
RNAC News
- 4 weeks ago - Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors - GlobeNewsWire
- 4 months ago - Cartesian: Maintaining Buy Rating For Expansion Of Descartes-08 For Myositis - Seeking Alpha
- 5 months ago - Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewsWire
- 6 months ago - Cartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 6 months ago - Cartesian Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 10 months ago - Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis - GlobeNewsWire